ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Expanding the ABCD1 mutation spectrum: a novel variant in X-linked adrenomyeloneuropathy.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionX-linked adrenoleukodystrophy (X-ALD) is the most common inherited peroxisomal disorder caused by pathogenic variants in the ABCD1 gene, leading to impaired peroxisomal β-oxidation of very-long-chain fatty acids (VLCFAs). Adrenomyeloneuropathy (AMN) is a frequent adult phenotype characterized by progressive spastic paraparesis and axonal neuropathy. We report the first case of AMN associated with a novel ABCD1 variant.
methodsClinical, neuroradiological, biochemical, neurophysiological, and genetic evaluations were performed in a 60-year-old male presenting with gait impairment and urinary dysfunction. Brain and spinal cord MRI, nerve conduction studies, plasma VLCFA analysis, and targeted next-generation sequencing for hereditary spastic paraplegia were carried out. Functional validation included Western blot analysis on cultured skin fibroblasts.
resultsNeurological examination showed spastic paraparesis with gait impairment. Brain MRI demonstrated confluent white matter hyperintensities, while spinal MRI revealed spinal cord atrophy. Plasma VLCFA levels were markedly elevated. Genetic testing identified a previously undescribed hemizygous ABCD1 variant, c.1922G > T (p.Gly641Val), classified as likely pathogenic according to ACMG criteria. The variant was absent from public databases. Western blot analysis demonstrated absent ABCD1 protein expression in patient-derived fibroblasts, supporting the pathogenicity of the variant.
conclusionsWe describe the first reported case of AMN associated with the novel ABCD1 c.1922G > T (p.Gly641Val) variant, expanding the mutational spectrum of X-ALD. The combination of biochemical findings and absent ALDP expression in patient-derived fibroblasts provides strong support for the pathogenicity of this previously undescribed variant. Reports integrating clinical, biochemical, genetic, and functional data may facilitate interpretation and classification of novel ABCD1 variants in clinical practice.
Indexed as
Identifiers
42603216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.